Cibeles Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 25.00 Cr
as on 02-07-2024
- Paid Up Capital ₹ 22.32 Cr
as on 02-07-2024
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 103.22%
(FY 2022)
- Profit 18.36%
(FY 2022)
- Ebitda -11.24%
(FY 2022)
- Net Worth 31.56%
(FY 2022)
- Total Assets 52.35%
(FY 2022)
About Cibeles Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 25.00 Cr and a paid-up capital of Rs 22.32 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Cibeles Pharmaceuticals Private Limited India is Sainath Iyer as CEO. Trushit Mehta, Dheer Shah, and Sainath Iyer serve as directors at the Company.
- CIN/LLPIN
U24100MH2019PTC379982
- Company No.
124043
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Cibeles Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sainath Iyer  | CEO | 18-Mar-2020 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Trushit Mehta | Nominee Director | 03-Mar-2020 | Current |
| Dheer Shah | Nominee Director | 03-Mar-2020 | Current |
| Sainath Iyer | Director and Ceo | 22-Oct-2019 | Current |
Financial Performance of Cibeles Pharmaceuticals.
Cibeles Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 103.22% increase. The company also saw a substantial improvement in profitability, with a 18.36% increase in profit. The company's net worth Soared by an impressive increase of 31.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cibeles Pharmaceuticals?
In 2022, Cibeles Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Spinos Life Science And Research Private LimitedActive 8 years 8 monthsDheer Shah is a mutual person
Bdr Lifesciences Private LimitedActive 31 years 3 monthsTrushit Mehta and Dheer Shah are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cibeles Pharmaceuticals?
Unlock and access historical data on people associated with Cibeles Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cibeles Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cibeles Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
